Group 1 - The core point of the article is that Weikang Pharmaceutical announced the convening of its fourth board meeting to discuss governance system revisions and provided details on its revenue composition for 2024 [1] - Weikang Pharmaceutical's revenue composition for 2024 is as follows: pharmaceutical manufacturing accounts for 57.79%, pharmaceutical wholesale and retail accounts for 41.01%, and other businesses account for 1.19% [1] - As of the report, Weikang Pharmaceutical has a market capitalization of 4 billion yuan [1] Group 2 - The article also mentions that Dapeng Industrial's strategic placement has significantly benefited its insiders, with a subscription price of 9 yuan and a first-day listing price of 118 yuan, resulting in a floating profit of 24.92 million yuan for the controlling shareholder and his brother [1]
维康药业：11月24日召开董事会会议